Progenitor Biological Bandages (PBB) have been continuously applied clinically in the Lausanne Burn Center for over two decades. Vast translational experience and hindsight have been gathered, specifically for cutaneous healing promotion of donor-site grafts and second-degree pediatric burns. PBBs constitute combined Advanced Therapy Medicinal Products, containing viable cultured allogeneic fetal dermal progenitor fibroblasts. Such constructs may partly favor repair and regeneration of functional cutaneous tissues by releasing cytokines and growth factors, potentially negating the need for subsequent skin grafting, while reducing the formation of hypertrophic scar tissues. This retrospective case-control study (2010–2018) of pediatric second-degree burn patients comprehensively compared two initial wound treatment options (i.e., PBBs versus Aquacel® Ag, applied during ten to twelve days post-trauma). Results confirmed clinical safety of PBBs with regard to morbidity, mortality, and overall complications. No difference was detected between groups for length of hospitalization or initial relative burn surface decreasing rates. Nevertheless, a trend was observed in younger patients treated with PBBs, requiring fewer corrective interventions or subsequent skin grafting. Importantly, significant improvements were observed in the PBB group regarding hypertrophic scarring (i.e., reduced number of scar complications and related corrective interventions). Such results establish evidence of clinical benefits yielded by the Swiss fetal progenitor cell transplantation program and favor further implementation of specific cell therapies in highly specialized regenerative medicine.
Background: This study reviews the surgical and functional outcomes of children diagnosed with a bilateral cleft lip and palate and treated by the same surgical team following specific surgical protocols 18 years after surgery and during the follow-up. Methods: Based on a single-center retrospective design, demographic and surgical data were gathered by the authors from international institutions. Most of the data were quantitative in nature, and descriptive statistical and non-parametric tests were employed for analysis. All children born with a bilateral cleft from 1982 to 2002 were considered. Children affected by a syndrome were excluded. Complications and speech results were the main items measured. Results: Thirty patients were selected; 73.3% were treated using the inverse Malek procedure, and 26.7% underwent a modified two-stage procedure. Seventy percent developed an oronasal fistula. An alveolar bone graft was performed in 83%, and 53.3% underwent Le Fort osteotomy. Thirty-six percent required a pharyngeal flap, with good speech results. The median number of times general anesthesia was used among all the interventions considered was 5.5 (4.25–6). Conclusions: This study presents the long-term results of using the inverse Malek procedure to treat children with a bilateral cleft lip and palate. It is shown that this is related to a high risk of developing a fistula, but has good long-term speech results.
Major burn injuries commonly present with hypoalbuminemia within the first 24 h. This study aimed to determine whether early hypoalbuminemia independently predicts mortality in severe burns. This single-center, retrospective cohort study included patients aged 14 years and older with burns covering at least 20% of their body surface area, admitted between January 2006 and December 2023 to a university teaching hospital. Exclusion criteria were admission more than 8 h postinjury or transfer to another unit within the first week. Albumin levels within the first 24 h were recorded. The primary outcome was 28-day mortality. A total of 161 patients were included with a median burn area of 38% (IQR 25-65) and an Abbreviated Burn Severity Index score of 9 (IQR 7-11.5). Mortality was 33% (53/161). While univariate analysis showed that lower albumin was associated with increased mortality (OR 0.91; 95% CI, 0.86-0.96; P = .001), this association was not significant after adjustment for burn severity (OR 0.99; 95% CI, 0.93-1.06, P = .87). The predictive value of minimum serum albumin for mortality was low with an area under the curve of 0.68. The optimal albumin threshold for predicting mortality was 24 g/L (sensitivity 81.0%, specificity 49.5%). Albumin levels below this threshold were not significantly associated with higher mortality in a time-to-event analysis (HR 1.72; 95% CI, 0.79-3.73, P = .169). Hypoalbuminemia in the first 24 h was not found to be an independent risk factor for 28-day mortality in this cohort, suggesting it as a marker of burn severity rather than an independent predictor.